2026-10-25
NanoViricides, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,403 −1.38%
S&P 7,720 −0.30%
GOLD $3,978 −1.32%
BTC $77,995 +0.28%
VIX 18.51 +7.62%
latest tape · as of 08:04 UTC
The Screen · Healthcare
NanoViricides, Inc.
NNVC · NYSE American · USD · Market cap $33M
Not yet scored1.40 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 7 days ago
Screened 2026-10-23 · the tape above runs as of 08:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price1.40 USD at the 23 Oct 2026 close
- Ethical screenNot yet scored
- Last reviewed23 Oct 2026 (7 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 1.40 against the desk's fair-value range, over the last year.
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price1.40 USD
Our investment reviews on this name
2026-10-02Read Markup1.44-2.8% to today Markdown gives way to Markup after a 7% rise in 4 weeks
2026-09-06Read Markdown1.34+4.5% to today Distribution gives way to Markdown after a 6% slide in 4 weeks
2026-08-07Read Distribution1.43-2.1% to today ✓Markup gives way to Distribution
2026-07-02Read Markup1.38+1.4% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
NanoViricides, Inc. holds its Markup at $1.40. The statistical read favours the sellers, held for 6 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 6 days |
| Price at the screen | $1.40 |
| Valuation | N/A trailing · -3.74 forward price to earnings |
| Values screen | Not scored |
| Beta | 1.79 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 0.00% | Below 33% | Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 8.60% | Below 33% | Cash held in interest-bearing accounts and securities is 8.6% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
NanoViricides, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
NanoViricides, clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -3.7x |
| EPS, trailing | -0.41 |
| EPS, forward | -0.35 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -101.5%not currently earning a positive return on equity |
| FCF yield | -14.22% |
| Current ratio | 2.66comfortably covers its short-term bills |
| Beta | 1.79much more volatile than the market |
| Short interest, float | 0.04% |
| 52-week range | 0.85 - 2.23 |
| Market cap | $33M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNNVC trades on NYSE American. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-20
Markup $1.37
-4.9% Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-10-02
Markup · changed $1.44
+7.5% Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-09-06
Markdown · changed $1.34
-6.3% Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.3% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-08-07
Distribution · changed $1.43
+3.6% Entry 4
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-07-18
Markup $1.38
+0.0% Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-07-03
Markup $1.38
+0.0% Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02
Markup $1.38
Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides Yahoo Finance · 17d ago
- NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 Yahoo Finance · 24d ago
- NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives Yahoo Finance · 25d ago
- NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials Yahoo Finance · 29 Sep 2026
- Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides Yahoo Finance · 28 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
LITSLite Strategy Inc
BDMDBaird Medical Investment Holdings Limited
NSPRInspireMD Inc
TELATELA Bio Inc
ABVCABVC BioPharma Inc
ACTUActuate Therapeutics Inc
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $1.49 | -10.4% | · | $896 | -10.4% |
| 2 months | $0.98 | +36.2% | · | $1,362 | +36.2% |
| 3 months | $1.16 | +15.1% | · | $1,151 | +15.1% |
| 6 months | $1.30 | +2.7% | · | $1,027 | +2.7% |
| 1 year | $1.53 | -12.8% | · | $873 | -12.8% |
| 2 years | $3.03 | -55.9% | · | $441 | -55.9% |
| 3 years | $1.11 | +20.3% | · | $1,203 | +20.3% |
| 5 years | $4.41 | -69.7% | · | $303 | -69.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NNVC does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.